Format

Send to

Choose Destination
Clin Cancer Res. 2015 Mar 15;21(6):1243-7. doi: 10.1158/1078-0432.CCR-14-0650. Epub 2014 Nov 25.

Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.

Author information

1
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York. Elda.Grabocka@nyumc.org.
2
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York.

Abstract

Of the genes mutated in cancer, RAS remains the most elusive to target. Recent technological advances and discoveries have greatly expanded our knowledge of the biology of oncogenic Ras and its role in cancer. As such, it has become apparent that a property that intimately accompanies RAS-driven tumorigenesis is the dependence of RAS-mutant cells on a number of nononcogenic signaling pathways. These dependencies arise as a means of adaptation to Ras-driven intracellular stresses and represent unique vulnerabilities of mutant RAS cancers. A number of studies have highlighted the dependence of mutant RAS cancers on the DNA damage response and identified the molecular pathways that mediate this process, including signaling from wild-type Ras isoforms, ATR/Chk1, and DNA damage repair pathways. Here, we review these findings, and we discuss the combinatorial use of DNA-damaging chemotherapy with blockade of wild-type H- and N-Ras signaling by farnesyltransferase inhibitors, Chk1 inhibitors, or small-molecule targeting DNA damage repair as potential strategies through which the dependence of RAS cancers on the DNA damage response can be harnessed for therapeutic intervention.

PMID:
25424849
PMCID:
PMC4359952
DOI:
10.1158/1078-0432.CCR-14-0650
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center